Antivenom for snakebite envenoming in Sri Lanka

The need for geographically specific antivenom and improved efficacy

D. E. Keyler, I. Gawarammana, J. M. Gutiérrez, K. H. Sellahewa, K. McWhorter, R. Malleappah

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Sri Lanka is a tropical developing island nation that endures significant economic and medical burden as a result of snakebite envenomation, having not only a high prevalence of envenomations, but also one of the highest incidence rates (200 snakebites/100,000 people/year) of venomous snakebite in the world (Kasturiratne et al., 2005). Ironically, the very snakes responsible for this human morbidity and mortality are a valuable biomedical and ecological national resource, despite the medical and economic consequences of envenomation. Currently, no snake antivenom is produced using venoms from native Sri Lankan snakes as immunogens, and there is a true need for an efficacious Sri Lanka, poly-specific snake antivenom. An approach to fulfilling this need via combining the scientific, technological and economical resources from Costa Rica and the United States with the knowledge and talent of Sri Lankan official governmental agencies, legal counsels, environmental, medical and veterinary academic institutions, and religious and cultural leaders has been initiated, coordinated and funded by Animal Venom Research International (AVRI), a nonprofit charity. This bridging of nations and the cooperative pooling of their resources represents a potential avenue for antivenom development in a developing country that suffers the consequences of few specific resources for the medical management of venomous snakebite. The desired final outcome of such an endeavor for Sri Lanka is, most importantly, improved medical outcomes for snakebite patients, with enhanced and expanded science and technology relating to snake venoms and antivenoms, and the collateral benefits of reduced economic cost for the country.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalToxicon
Volume69
DOIs
Publication statusPublished - 01-07-2013
Externally publishedYes

Fingerprint

Antivenins
Snake Bites
Sri Lanka
Snakes
Venoms
Medical Economics
Economics
Developing Countries
Snake Venoms
Charities
Costa Rica
Developing countries
Aptitude
Animals
Islands
Technology
Morbidity
Costs and Cost Analysis
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Keyler, D. E., Gawarammana, I., Gutiérrez, J. M., Sellahewa, K. H., McWhorter, K., & Malleappah, R. (2013). Antivenom for snakebite envenoming in Sri Lanka: The need for geographically specific antivenom and improved efficacy. Toxicon, 69, 90-97. https://doi.org/10.1016/j.toxicon.2013.01.022
Keyler, D. E. ; Gawarammana, I. ; Gutiérrez, J. M. ; Sellahewa, K. H. ; McWhorter, K. ; Malleappah, R. / Antivenom for snakebite envenoming in Sri Lanka : The need for geographically specific antivenom and improved efficacy. In: Toxicon. 2013 ; Vol. 69. pp. 90-97.
@article{53a9927e573c4dc7b96c34bdd1b7aa17,
title = "Antivenom for snakebite envenoming in Sri Lanka: The need for geographically specific antivenom and improved efficacy",
abstract = "Sri Lanka is a tropical developing island nation that endures significant economic and medical burden as a result of snakebite envenomation, having not only a high prevalence of envenomations, but also one of the highest incidence rates (200 snakebites/100,000 people/year) of venomous snakebite in the world (Kasturiratne et al., 2005). Ironically, the very snakes responsible for this human morbidity and mortality are a valuable biomedical and ecological national resource, despite the medical and economic consequences of envenomation. Currently, no snake antivenom is produced using venoms from native Sri Lankan snakes as immunogens, and there is a true need for an efficacious Sri Lanka, poly-specific snake antivenom. An approach to fulfilling this need via combining the scientific, technological and economical resources from Costa Rica and the United States with the knowledge and talent of Sri Lankan official governmental agencies, legal counsels, environmental, medical and veterinary academic institutions, and religious and cultural leaders has been initiated, coordinated and funded by Animal Venom Research International (AVRI), a nonprofit charity. This bridging of nations and the cooperative pooling of their resources represents a potential avenue for antivenom development in a developing country that suffers the consequences of few specific resources for the medical management of venomous snakebite. The desired final outcome of such an endeavor for Sri Lanka is, most importantly, improved medical outcomes for snakebite patients, with enhanced and expanded science and technology relating to snake venoms and antivenoms, and the collateral benefits of reduced economic cost for the country.",
author = "Keyler, {D. E.} and I. Gawarammana and Guti{\'e}rrez, {J. M.} and Sellahewa, {K. H.} and K. McWhorter and R. Malleappah",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.toxicon.2013.01.022",
language = "English",
volume = "69",
pages = "90--97",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Elsevier Limited",

}

Keyler, DE, Gawarammana, I, Gutiérrez, JM, Sellahewa, KH, McWhorter, K & Malleappah, R 2013, 'Antivenom for snakebite envenoming in Sri Lanka: The need for geographically specific antivenom and improved efficacy', Toxicon, vol. 69, pp. 90-97. https://doi.org/10.1016/j.toxicon.2013.01.022

Antivenom for snakebite envenoming in Sri Lanka : The need for geographically specific antivenom and improved efficacy. / Keyler, D. E.; Gawarammana, I.; Gutiérrez, J. M.; Sellahewa, K. H.; McWhorter, K.; Malleappah, R.

In: Toxicon, Vol. 69, 01.07.2013, p. 90-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antivenom for snakebite envenoming in Sri Lanka

T2 - The need for geographically specific antivenom and improved efficacy

AU - Keyler, D. E.

AU - Gawarammana, I.

AU - Gutiérrez, J. M.

AU - Sellahewa, K. H.

AU - McWhorter, K.

AU - Malleappah, R.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Sri Lanka is a tropical developing island nation that endures significant economic and medical burden as a result of snakebite envenomation, having not only a high prevalence of envenomations, but also one of the highest incidence rates (200 snakebites/100,000 people/year) of venomous snakebite in the world (Kasturiratne et al., 2005). Ironically, the very snakes responsible for this human morbidity and mortality are a valuable biomedical and ecological national resource, despite the medical and economic consequences of envenomation. Currently, no snake antivenom is produced using venoms from native Sri Lankan snakes as immunogens, and there is a true need for an efficacious Sri Lanka, poly-specific snake antivenom. An approach to fulfilling this need via combining the scientific, technological and economical resources from Costa Rica and the United States with the knowledge and talent of Sri Lankan official governmental agencies, legal counsels, environmental, medical and veterinary academic institutions, and religious and cultural leaders has been initiated, coordinated and funded by Animal Venom Research International (AVRI), a nonprofit charity. This bridging of nations and the cooperative pooling of their resources represents a potential avenue for antivenom development in a developing country that suffers the consequences of few specific resources for the medical management of venomous snakebite. The desired final outcome of such an endeavor for Sri Lanka is, most importantly, improved medical outcomes for snakebite patients, with enhanced and expanded science and technology relating to snake venoms and antivenoms, and the collateral benefits of reduced economic cost for the country.

AB - Sri Lanka is a tropical developing island nation that endures significant economic and medical burden as a result of snakebite envenomation, having not only a high prevalence of envenomations, but also one of the highest incidence rates (200 snakebites/100,000 people/year) of venomous snakebite in the world (Kasturiratne et al., 2005). Ironically, the very snakes responsible for this human morbidity and mortality are a valuable biomedical and ecological national resource, despite the medical and economic consequences of envenomation. Currently, no snake antivenom is produced using venoms from native Sri Lankan snakes as immunogens, and there is a true need for an efficacious Sri Lanka, poly-specific snake antivenom. An approach to fulfilling this need via combining the scientific, technological and economical resources from Costa Rica and the United States with the knowledge and talent of Sri Lankan official governmental agencies, legal counsels, environmental, medical and veterinary academic institutions, and religious and cultural leaders has been initiated, coordinated and funded by Animal Venom Research International (AVRI), a nonprofit charity. This bridging of nations and the cooperative pooling of their resources represents a potential avenue for antivenom development in a developing country that suffers the consequences of few specific resources for the medical management of venomous snakebite. The desired final outcome of such an endeavor for Sri Lanka is, most importantly, improved medical outcomes for snakebite patients, with enhanced and expanded science and technology relating to snake venoms and antivenoms, and the collateral benefits of reduced economic cost for the country.

UR - http://www.scopus.com/inward/record.url?scp=84878502503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878502503&partnerID=8YFLogxK

U2 - 10.1016/j.toxicon.2013.01.022

DO - 10.1016/j.toxicon.2013.01.022

M3 - Article

VL - 69

SP - 90

EP - 97

JO - Toxicon

JF - Toxicon

SN - 0041-0101

ER -